Status: Recruiting
Secukinumab Open Label Roll-over Extension Protocol
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
Participants needed: 1,000
Trial details
Phase: Phase 4Age: 6-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Aug 18, 2026Locations: 168
Eligibility criteria
Signed informed consent must be obtained for adult participants before any asses... [+4]
Participant has prematurely discontinued study treatment in the parent protocol. [+1]